Interface Biologics is a commercial stage privately held company that develops transformative biomedical polymer technology to improve the safety and effectiveness of medical devices. IBI’s primary technology focus areas are anti-thrombogenic additives that reduce thrombosis in blood contacting medical devices and polymer enabled drug delivery devices.
Looking for a particular Interface Biologics employee's phone or email?
The Interface Biologics annual revenue was $5 million in 2026.
1 people are employed at Interface Biologics.
Interface Biologics is based in Toronto, Ontario.
The NAICS codes for Interface Biologics are [33, 339].
The SIC codes for Interface Biologics are [38, 384].